Fresenius Medical Care AG & Co. KGaA / Key word(s): Forecast
Fresenius Medical Care AG & Co. KGaA gives early preliminary indicative guidance for 2019
06-Dec-2018 / 22:35 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Fresenius Medical Care, the world's largest provider of dialysis products and services, has decided to update the market early on its indicative preliminary assumptions for the business development in 2019. For 2019, Fresenius Medical Care currently broadly assumes solid comparable1revenue growth and the comparable1net income to be around the level of fiscal year 2018.
Fresenius Medical Care is currently reviewing all factors as part of its budgeting process and plans to publish the guidance for 2019, at the usual level of detail, along with the company's fiscal year 2018 results, which are planned to be released on February 20, 2019.
"comparable" is on a constant currency basis and reflects an adjustment for those effects that are as per the company's view not related to the company's operating business performance such as, for example, the effects of IFRS 16, sizeable portfolio changes like the divestiture of Sound Inpatient Physicians Holdings, the pending acquisition of NxStage Medical Inc., or other effects of one-time nature like FCPA-related charges or the cost of the 2018 U.S. ballot initiatives. For the preliminary indicative 2019 guidance the "comparable" 2018 basis translates roughly at current currencies for revenue in a range of 15,850 - 16,050 EUR million and for net income in a range of 1,350 - 1,365 EUR million. This is subject to fluctuations in the currency rates in the fourth quarter of 2018.
Person making the notification:
Dr. Dominik Heger
SVP Investor Relations & Corporate Communications
P. +49 6172 609 2601
Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,872 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 329,085 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the company provides related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company's website at www.freseniusmedicalcare.com.
The envisaged date of February 20, 2019 for announcement on the guidance for 2019 is subject to compliance with applicable laws, i.e. if applicable legal regimes so demand, the publication may occur at an earlier point in time.
06-Dec-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de